A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2010-05-01

Summary

The primary purpose of this study is to examine the safety of volociximab in combination with a standard treatment of carboplatin and paclitaxel in subjects previously untreated with chemotherapy for advanced stage (IIIB/IV) non-small cell lung cancer (NSCLC).

• Phase: Phase 1

Details

• Lead Sponsor: Abbott; AbbVie
• Treatments: Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Carboplatin; Paclitaxel; Volociximab